NPC Archive Item: New legislation – Bribery Act 2010

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 17 May 2011 The Bribery Act 2010 comes into force on 1st July 2011. This aims to tackle bribery and corruption in both the public and private sector. NHS […]

NPC Archive Item: Apixaban after hip replacement surgery has some benefit compared to enoxaparin on a mixture of disease- and patient-orientated outcomes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 20 April 2011 In ADVANCE-3 (n=5,407), oral apixaban 2.5mg twice daily was associated with lower rates of a composite endpoint of both disease and patient-oriented outcomes than subcutaneous enoxaparin […]

NPC Archive Item: Rivaroxaban▼ may offer an alternative anticoagulation option for acute and long-term treatment of venous thrombosis

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 14th February 2011 Two phase III EINSTEIN trials of rivaroxaban▼ (Xarelto®) have recently been published as a single paper. The EINSTEIN–DVT (Acute) Study (n=3,449) found that rivaroxaban was non-inferior […]

NPC Archive Item: Dabigatran etexilate▼ has benefits over warfarin in patients with atrial fibrillation, but long-term evidence on efficacy and safety is required

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 November 2010 An editorial in the British Medical Journal discusses the role of dabigatran etexilate▼ in patients with atrial fibrillation (AF) and concludes that it has some benefits but […]

NPC Archive Item: DURATION-3; when added to metformin or metformin plus a sulphonylurea, weekly exenatide improves disease-orientated outcomes compared with insulin glargine

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 Long-acting exenatide 2mg once weekly was more effective at reducing HbA1c than insulin glargine (titrated to glucose targets), when added to metformin or metformin plus sulphonylurea, […]

NPC Archive Item: DURATION-2; weekly exenatide in type 2 diabetes has disease-orientated outcome benefits when compared with metformin plus either sitagliptin▼ or pioglitazone▼

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 Exenatide 2mg once weekly injection was more effective at reducing HbA1c than maximum oral doses of either sitagliptin▼ or pioglitazone▼, when added to metformin, in the […]

NPC Archive Item: Extended DURATION-1 trial of exenatide weekly in type 2 diabetes demonstrates sustained reduction in HbA1c; no patient-orientated outcomes reported

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 We have previously discussed the 30-week DURATION-1 trial of long-acting exenatide 2mg once weekly versus 10micrograms exenatide▼ twice daily in adults with type 2 diabetes (T2DM). In […]